Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
- 3.7k Downloads
The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to stablish practical guidelines for the diagnoses, staging and management of these patients. This paper summarizes the main conclusions of the working group. Patients with suspected pancreatic ductal adenocarcinoma should be rapidly evaluated and referred to high-volume centers. Multidisciplinary supervision is critical for proper diagnoses, staging and to frame a treatment plan. Surgical resection together with chemotherapy offers the highest chance for cure in early stage disease. Patients with advanced disease should be classified in treatment groups to guide systemic treatment. New chemotherapeutic regimens have resulted in improved survival. Symptomatic management is critical in this disease. Enrollment in a clinical trial is, in general, recommended.
KeywordsPancreatic cancer Diagnosis Treatment Consensus guidelines
Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, currently stands as the third most common cause of cancer related deaths . In 2008 a total of 70,000 of were diagnosed in Europe [2, 3]. Rates of new cases of pancreatic cancer have increased on average 0.8% annually over the last ten years. The current 5- and 10-year survival rates at 7.2% and below 4%, respectively .
The aim of the present consensus guidelines is to provide a general overview of the diagnosis, a more global patient´s classification, not just based on performance status, treatment, and management of associated complications of patients with PDAC. These guidelines are the result of expert consensus meetings that took place during the months of September to December 2015 sponsored by Fundación ECO, where a total of forty-two medical oncologists, radiotherapists, surgeons, radiologists, pathologists, endocrinologists, gastrointestinal specialists and palliative care specialists shared their opinions. These recommendations are based on the results of clinical trials, retrospective, observational studies, as well as the group of experts´ opinion (levels of evidence: quality of evidence: I–III; strength of recommendation: A–E) .
PDAC: signs and symptoms
The absence of specific manifestations, together with its biological aggressiveness, results in delayed diagnosis in more than 80% of cases. The most common symptoms include fatigue, anorexia, weight loss, abdominal pain and dark urine . Sixty to 70% of tumors originate in the pancreatic head, 20–25% in the body and tail and in 10–20% there is a diffuse involvement of the gland . While tumors in the pancreatic head tend to be diagnosed at earlier stages because of the jaundice associated with bile duct obstruction, tumors in the body and tail are usually detected in advanced stages. Tumor with obstructive jaundice may be associated with palpable gallbladder (Courvoisier sign). Head tumors may also be associated with steatorrhea as a consequence of exocrine pancreatic insufficiency and obstruction of the pancreatic duct. Although with low specificity, the combination of diabetes mellitus (DM) of recent onset associated with weight loss should lead to suspicion PDAC . About one in 125 (0.85%) patients with new-onset DM presents PDAC, eight times more than expected, compared to the general population . Patients with newly diagnosed DM without metabolic syndrome and difficult glycemic control should be evaluated to rule out PDAC  (IIB). Special attention should be paid to patients that present the following symptoms: weight loss, abdominal pain, DM of recent onset or with poor disease control. Patients with advanced stages of PDAC may have epigastric palpable mass, hepatomegaly secondary to liver metastases, ascites caused by peritoneal carcinomatosis, pain, vascular and nerve infiltration and/or gastric outlet obstruction. The PDAC is associated with arterial and venous (hypercoagulable state) thrombosis such as Trousseau syndrome (migratory superficial vein thrombosis. PDAC may also be associated with palpable supraclavicular lymph nodes (Virchow), anterior axillary (Irish) or periumbilical mass (Sister Mary Joseph).
Familial PDAC and hereditary PDAC
The International Cancer of the Pancreas Consortium Screening (CAPS) recommends screening of PDAC in high-risk individuals (HRI) or families with familial pancreatic cancer (FPC), although this is not yet included in routine clinical practice  (IIIC). PDAC screening programs should be performed in high-volume centers that have multidisciplinary teams with experience in the screening and treatment of the disease. HRI are considered as those who have at least 5–10 times increased risk of PDAC  and include families with at least two first-degree relatives affected, or ≥3 individuals regardless of the degree of kinship. In addition, subjects with Peutz–Jeghers syndrome, hereditary pancreatitis, or those affected by other hereditary cancer syndromes (germline mutations in the BRCA genes, familial melanoma or colorectal cancer hereditary) with a case of PDAC in the family .
The best screening techniques for HRI is magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) and upper gastrointestinal endoscopic ultrasound (EUS) [11, 12, 13, 14, 15] (Algorithm 1). Open image in new window Screening tests aim to detect small pancreatic solid tumors (≤1 cm), irregular pancreatic duct, and pancreatic precursor lesions such as intraductal papillary mucinous neoplasm (IPMN), which are usually present as cysts . The prevalence of suspected cystic pancreatic lesions is 33–45% in HRI [11, 15]. The CAPS recommend starting screening at age 50 years, or ten years before the age of the youngest case in the family  with annual exams if no pancreatic lesions are observed  (IIIB). These intervals could be modified at the discretion of the multidisciplinary tumor committee. If suspicious abnormalities are detected, surgery is indicated although the current available evidence is limited [11, 12, 13, 14, 15, 16].
In patients with suspected PDAC based on medical history and/or physical exam, the primary diagnostic approach to the patient with PDAC is radiological. An abdominal ultrasound is often the first test performed in patients with abdominal pain and/or jaundice. US can detect dilatation of the bile duct or pancreatic duct and the presence of a pancreatic mass. However, the sensitivity for detecting pancreatic tumors is low and ranges between 50 and 70% . Computer tomography (CT) scan is the gold standard technique in the evaluation of patients with suspected PDAC (IIA). The study of a pancreatic mass must include a biphasic CT performed with an arterial phase (40–50 s) and portal venous phase (65–70 s) [7, 17, 18, 19]. In most cases, PDAC is seen in the arterial phase as a hypodense pancreatic lesion, with poorly defined margins . Furthermore, CT scan detects the vascular involvement (arterial and venous), extra-pancreatic local extension, presence of lymph nodes, and detection of liver or peritoneal nodules . The availability of a high-quality multidetector CT (preferably ≥16 detectors) combined with experience in the interpretation of these studies has shown a more accurate preoperative staging and better patients´ management . Magnetic resonance imaging (MRI) has equal sensitivity and specificity than CT for staging PDAC, but its use is not widespread because of its high cost and reduced availability and is usually reserved for difficult cases, cystic neoplasms of the pancreas and to explore biliary anatomy as well . Radiology report should follow a standard format [18, 19].
Upper gastrointestinal endoscopy is useful to take biopsies of tumors infiltrating the duodenum as well as for palliative decompression of the duodenum and/or bile duct . Endoscopic retrograde cholangiopancreatography (ERCP) is restricted to cases with obstruction of the bile duct because is associated with significant adverse effects and has low profitability of achieving a histological diagnosis (20%) . Endoscopic ultrasound (EUS) is an important complementary examination in the diagnosis and staging of PDAC as it permits examining the primary tumors, relationship with neighboring structures as well as obtaining tissue for pathological diagnoses . The sensitivity and specificity of EUS-guided tumor fine needle aspiration (FNA) are 90 and 98%, respectively . It should be noted, however, that patients with clinical and radiological suspected PDAC with resectable do not need a pathological diagnoses before surgical resection (IIIB). Pathological diagnoses are needed in patients with atypical presentation and in those with locally advanced disease that are managed with chemotherapy and/or radiation therapy (IIIB).
Pathological diagnoses and classification
In the presence of suspicious lesions that are resectable, a tumor biopsy prior surgery is not required. Likewise, because of the complexity to obtain it as well as the limitations on its interpretation an intraoperative biopsy is not required [7, 21] (IIIB). A pathological diagnosis is always required in patients with unresectable or borderline lesions to be managed with chemotherapy and/or radiation therapy as well as in patients with amenable to treatment with metastatic disease  (IIIB).
The technique of choice to obtain tissue for pathological diagnoses depends on the location of the lesion and the stage of the disease. For primary tumors, a EUS-FNA is the safest procedure with highest sensitivity and specificity that can also provide additional staging information . In patients with metastatic liver disease, a percutaneous US- or CT-guided biopsy is the procedure of choice [7, 21] (IIIB). If a biopsy does not confirm malignancy, it should be repeated atleast once. If during surgery the tumor is unresectable, histological diagnosis should be made (IIIB).
Classification of pancreatic tumors (WHO 2010 classification)
Acinar cell cystadenoma
Pancreatic intraepithelial neoplasia type 3 (PanIN-3)
Intraductal papillary mucinous neoplasm with low or intermediate grade dysplasia
Intraductal papillary mucinous neoplasms
Tubulo-papillary intraductal neoplasia
Mucinous cystic dysplasia neoplasia with low or intermediate grade
Mucinous cystic neoplasm with high-grade dysplasia
Colloid carcinoma (non-cystic mucinous carcinoma)
Cell carcinoma signet ring
Undifferentiated carcinoma with osteoclast-like giant cells
Acinar cell carcinoma
Cystoadenocarcinoma acinar cells
Intraductal papillary mucinous neoplasm or associated with invasive carcinoma
Mixed acinar-ductal carcinoma
Mixed acinar-neuroendocrine carcinoma
Mixed-neuroendocrine carcinoma acinar-ductal
Mixed ductal-neuroendocrine carcinoma
Mucinous cystic neoplasm associated with invasive carcinoma
Pseudopapillary or solid neoplasia
Pancreatic neuroendocrine microadenoma
Neuroendocrine tumor (NET)
Pancreatic, not functioning G1, G2 NET
Neuroendocrine carcinoma (NEC)
Large cell NEC
Small cell NEC
NET serotonin producer (carcinoid)
Although many biomarkers have been studied for PDAC, only carbohydrate antigen 19.9 (CA 19.9) has proven useful and therefore, it is the only biomarker routinely used  (IA). For diagnoses, it has a sensitivity ranging between 70 and 92% and a specificity of 68–92% depending on tumor size. False positive results are associated with benign diseases such as pancreatitis, cirrhosis, acute cholangitis, and other diseases causing of cholestasis. Determining CA 19.9 is a complementary test in the diagnoses and management of PDAC . In patients with resectable disease, plasma levels >100 U/mL values predict the presence of occult metastatic disease. In advanced disease, elevated CA 19.9 is considered as unfavorable prognostic factor [25, 26]. However, given its low positive predictive value, particularly in asymptomatic individuals, is not recommended as a screening marker .
Timeline for diagnosis and management
Because PDAC is very aggressive, it is recommended to reduce the diagnostic time as much as possible to rapidly initiate treatment . In a study in patients with advanced PDAC it was estimated that the average doubling time of pancreatic tumor was 40–60 days . A month from the onset of the first symptoms or suspicious signs is a reasonable goal (IIIB).
The National Cancer Strategy Health System (2010) states that the time from therapeutic decision until the actual start of treatment should be less than 2 weeks for surgical treatment, one week for chemotherapy and 4 weeks (including treatment planning) for radiation therapy  (IIIB). Strategies to minimize time to diagnoses include raising awareness in the general population and among health professionals, rapid diagnostic protocols for patients with suspected lesion in primary care settings as well as preferential referral pathways to specialize care and treatment centers. PDAC, like any other complex tumor, should be managed in high referral centers by multidisciplinary teams: Medical oncologists, pathologists, radiotherapist, GI specialist, surgeons and radiologists  (IIIB).
Staging and disease classification
Pancreatic cancer can be staged, based on imaging and pathological studies, in stages as per the TNM classification [31, 32]. However, from a management perspective, patients are better classified based on the extension of disease in resectable, borderline resectable, locally advanced unresectable and metastatic (IIIA).
Patients’ classification, according to treatment perspective (IIIB)
Patient suitable for chemotherapy treatment without limitations
The presence of ALL the following factors
Age ≤75 years
Bilirubin ≤1.5 ULN
Good nutritional status (serum albumin >2.5 mg/dl, weight lost <10% over the last 3–6 months and BMI >20 kg/m2)
Lack of co-morbidities
Patient suitable for chemotherapy with limitations
The presence of AT LEAST ONE of the following factors
ECOG 2 (which can lead to KPS 70%)
Age >75 years
Mild to moderate neurological or endocrine-metabolic organ dysfunction; in case of liver dysfunction, hyperbilirubinemia >1.5 × ULN (once optimized if obstructive causes are present, for example with biliary stent) marks the degree of dysfunction. It is considered appropriate to adjust the dose, for example, using GEM at 600-800 mg/m2 and nab paclitaxel 75–100 mg/m2) 
Cardiac dysfunction, especially a recent ischemic event; acute, symptomatic, severe TED such as PE with hemodynamic instability or DVT with risk and limb amputation 
BMI <20 kg/m2 or >10% weight loss in 3–6 months
Patient not suitable for chemotherapy treatment
The presence of AT LEAST ONE of the following factors
ECOG 3-4 (which may result in KPS ≤ 60%). Active treatment will be initiated in patients with ECOG 3 secondary to the disease (not to their previous comorbidities) without any severe organ dysfunction, thus moving this subgroup of patients to the “candidate for chemotherapy treatment with limitations” group
Severe organ dysfunction: neurological (e.g., severe cognitive impairment, Alzheimer’s type); endocrine-metabolic, infectious (uncontrolled HIV), renal, hepatic dysfunctions, etc
Practical considerations in treatment decision process
The treatment plans for patients with PDAC patients should be made individually. A complete staging process is essential to determine the extent of the tumor that drives treatment plan and prognosis. In parallel, patient´s status, which is linked to its ability to tolerate an aggressive treatment, should be defined. This includes the functional status as determine by the Karnofsky Performance Scale (KPS) and/or the Eastern Cooperative Oncology Group (ECOG). Patients with KPS of less than 60–70% or ECOG less than 0–1 are limited to receive aggressive chemotherapy. For elderly patients, it is also advisable to use geriatric scales such as the Barthel scale that assesses the degree of autonomy in basic activities of daily living . The assessment of nutritional status as measured by physical exam (weight, body mass index, presence of edema), recent weight lost (>10% over 6 months); plasma protein levels (albumin, prealbumin, transferrin) is crucial . Validated nutritional scales such as Mini Nutritional Assessment are useful in this regard. In addition, a life expectancy of >3 months is usually needed to administer cancer treatment. Mechanical problems caused by tumor masses such as bile duct and bowel obstruction need to be assessed and corrected prior to treatment commencement. Finally, patient priorities and preferences need to be considered (IIIA).
Resectable disease/borderline resectable disease
Neoadjuvant treatment, which is the treatment with chemotherapy and/or radiotherapy administered before surgical resections, aims to increase overall survival by increasing the rate of R0 resection and early treatment of micrometastatic disease. In addition, preoperative treatment may lead to avoiding unnecessary surgical resection in patients with aggressive tumors that develop early progression.
It should be noted, however, that there are no randomized phase 3 studies to support any of these assumptions. Prior studies suggest an increment in the rate of R0 resections [39, 40, 41]. Most studies reported thus far were conducted with old, less effective chemotherapy regiments and the data available with modern regimens [gemcitabine (GEM)/nab paclitaxel, FOLFIRINOX], came from single-center trials [35, 42, 43, 44, 45, 46, 47].
Here, we discuss preoperative management of patients with resectable or borderline resectable disease. Prior to treatment initiation, it is important to have pathological diagnosis as well as normalized bile duct drainage. Endoscopically placement of a metal stent is the procedure of choice to palliate obstructive jaundice (IIIB).
For patients with resectable disease neoadjuvant treatment cannot be recommended outside a clinical trial. However, preoperative treatment is one of the available approaches in patients with borderline resectable disease (IIB). The chemotherapy treatments used should be those associated with higher response rate in patients with metastatic disease (GEM/nab paclitaxel, FOLFIRINOX) [35, 46] (IIB). Currently there is no evidence to recommend one versus the other and the decision should be based on patients´ characteristics and center experience. In general, treatment should be administered for 3–4 months with a reassessment and multidisciplinary discussion afterwards (IIB). Patients with responding tumors by either radiological criteria or CA 19.9 could proceed to surgical resection [48, 49] (IIB). Radiotherapy the alone is not recommended and should be combined with either fluoropyrimidines or GEM (IIB). IMRT is associated with reduced toxicity and should be used when available. Patients who receive chemo-radiation should wait four to eight weeks before attempting surgical resection (IIB).
Radiological evaluation must be conducted after neoadjuvant treatment. Lack of objective radiological response should not be a criterion to rule out surgical resection  (IIB). Those patients with suspected disease progression by either elevated CA 19.9 without radiological evidence of disease progression should be carefully evaluated and PET scan and laparoscopy should be considered (IIB). Patients with documented metastatic progression are not candidates for surgery and should be managed as such (IIB).
Resectability criteria 
Absence of tumoral contact with CT, MSA or CHA
Absence of tumoral contact with SMV or PV or contact ≤180° without irregularities in the venous contour
Head of the pancreas and uncinate process
Solid tumoral contact with CHA, without extension to CT or HA bifurcation, that allows resection and complete and safe vascular reconstruction
Solid tumoral contact with SMA ≤180°
The presence of arterial anatomic variants should be evaluated (i.e., right accessory HA, replacement of right HA, replacement of CHA as well as source of replaced or accessory artery) and the presence and degree of tumoral contact due to their influence when planning the surgical procedure
Body and tail of the pancreas
Solid tumoral contact with CT ≤ 180°
Solid tumoral contact with CT > 180° without aorta involvement and with intact GDA (there is no consensus on this criteria and can be included in the non-resectable category)
Solid tumoral contact with SMV or PV >180°, contact ≤180° with irregularities in the venous contour or venous thrombosis but with adequate proximal and distal ends that allow safe vascular resection and replacement
Solid tumor contact with IVC
Distant metastasis (including metastasis in non-regional lymph nodes)
Head of the pancreas and uncinate process
Solid tumoral contact with SMA or CT >180°
Solid tumoral contact with the first jejunal branch of SMA
Body and tail of the pancreas
Solid tumoral contact with SMA or CTC > 180°
Solid tumoral contact with CT and aortic infiltration
Head of the pancreas and uncinate process
Tumoral infiltration or thrombosis (thrombosis may not be tumoral) in SMV or PV, that does not allow reconstruction
Contact with the most proximal jejunal vein that drains in SMV
Body and tail of the pancreas
Tumoral infiltration or thrombosis (the thrombosis may not be tumoral) in SMV or PV, that does not allow reconstruction
In addition to stage classifications, a complete assessment of operative risk should be performed. Considering the high morbimortality of pancreatic cancer resection, its assessment is of great importance. Classic surgical risk scales, such as Apache, ASA and POSSUM, do not predict accurately the morbidity after pancreatic surgery. Other more recent classification such as the one published by Braga, as well as the Preoperative Pancreatic Resection (PREPARE) and SOAR (Surgical Outcomes Analysis and Research) scores are based on the integration of multiple parameters and appear more accurate [56, 57, 58, 59].
Prior to surgical resection, it is critical to gain an adequate nutritional status and either nutritional supplements or even parenteral nutrition should be considered for 1–2 weeks prior to surgery in malnourished patients. In patients with large tumors, particularly of the tail of the pancreas, borderline resection and high tumor marker, a diagnostic laparoscopy should be considered prior to laparotomy.
For patients with tumors in the head of the pancreas, the procedure of choice is the duodenal pancreatectomy (Whipple procedure), which includes en bloc resection of the head of the pancreas, duodenum, gall bladder and bile duct, together with regional lymphadenectomy  (IA). Pylorus preserving pancreatectomy is equivalent to classic Whipple with regards to morbimortality and outcome and the selection of surgery type depends on surgeon preference. Other procedures such as extended pancreatectomy, total pancreatectomy, and extended lymphadenectomy are reserved for selected cases [60, 61].
Patients with tumors of the body or tail of the pancreas are treated with distal pancreatectomy.
As mentioned above, laparoscopy can detect small peritoneal implants or liver metastasis not visible by CT scan and is often used in patients with high risk of metastatic disease  (IIB). In addition, for patients with tumors in the body and tail of the pan, laparoscopy resection with or without robot assistance, is gaining acceptance . Finally, vascular involvement has been traditionally considered a formal contraindication for resection [64, 65]. More recently, however, venous resection and reconstruction is accepted as an optimal surgical procedure and is not associated with worse prognosis. However, arterial resection and reconstruction is still considered an investigational approach [51, 57, 65].
Adjuvant treatment is recommended in patients who undergo an R0/R1 resection with a PT1-4/N0-1M0, with an ECOG PS 0–1 and proper nutritional status [66, 67]. Treatment of patients with ECOG 2 needs to be individualized [66, 67].
It is recommended that adjuvant treatment is initiated within the next 12 weeks after surgery in patients who do not have any active infection, any serious postsurgical complication or presents with signs or symptoms of recurrent disease. There is no consensus on the adjuvant treatment in patients who have received neoadjuvant treatment [7, 68, 69, 70]. Those patients need to be evaluated in a multidisciplinary board. In general, adjuvant treatment in this population is still considered investigational. As a general rule, patients who have received neoadjuvant treatment should receive adjuvant treatment to complete a total of six months of treatment (IIIB).
With regards to the role of radiation therapy, there is even less information and could be considered in those patients with positive margin providing was not administered in the preoperative period (IIC). Prior to adjuvant chemotherapy commencement patient needs to be evaluated with a CBC, chemistry, renal function test, albumin, LDH and CA 19.9 levels [7, 71, 72, 73]. A CT of the chest, abdomen and pelvis is required to document lack of disease progression [18, 71, 73]. Currently, and until the results of ongoing studies are available, the recommended treatment is single agent GEM, or 5-FU and leucovorin (LV), for a total of six months [66, 67, 74, 75, 76] (IA). The results of the recent clinical trial ESPAC-4 support the use of GEM + capecitabine in this setting  (IA). The role of radiation therapy is less defined and should be considered for patients with positive margins and in selected cases with lymph node positive disease [75, 76, 77, 78, 79, 80, 81, 82] (IC).
Those patients with positive margins and neoadjuvant treatment that did not include radiation therapy are a particularly suitable group for postoperative radiotherapy. Currently, there is no biomarker predictive of outcome in this patient population and CA 19.9 is the only prognostic indicator . Once treatment is completed, patient should be followed every three months with measurement of CA 19.9 levels and a physical exam [7, 83, 84, 85] (IIIB). A CT scan should be performed every 6 months during the first 2–3 years after surgery and yearly thereafter [7, 83, 84, 85].
Management of patients with locally advanced disease
The management of patients with locally advanced disease is one of the most controversial areas in the treatment of PDAC due to the paucity of well controlled, randomized clinical trials. The goal in treating these patients is to improve survival which is better achieved if a complete surgical resection is feasible. Patients with locally advanced disease need to be evaluated like any other patient with PDAC with special attention to nutritional status, ECOG performance status, symptoms related to tumor local growth (pain, bowel and/or bile duct obstruction). The presence of bile duct or bowel obstruction need to be corrected before treatment is initiated. For patients who are candidates of chemotherapy treatment without limitations, this is in general the recommended approach (Table 2). While there are no data with regards to the most efficient regimen in this particular setting, current trend is to use either GEM-nab paclitaxel or FOLFILRINOX based on the data available for patients with advanced disease [35, 46, 86, 87] (IIB). Chemotherapy is usually administered for 3–4 months followed by assessment of tumor response. In patients with partial response that allows surgical resection, it could be a treatment option. In the remaining patients with partial response and those with stable disease, chemotherapy treatment as well as consolidation with chemotherapy and radiotherapy are valid options.
The recent data from the LAP007 study (Phase III study that compared chemoradiotherapy and chemotherapy in patients with a locally advanced pancreatic cancer controlled after four months of GEM with or without erlotinib) indicates that there are no survival benefits for chemo-radiation as compared to continuing chemotherapy alone, although it decreased the risk of local progression and improved PFS  (IA).
It should be noted, however, that this study used conventional external beam radiation and gemcitabine-based chemotherapy and the results cannot be extrapolated to those obtained with new chemotherapy regimens and more modern radiation techniques (IMRT). Data from the SCALOP trial (Phase II study of induction chemotherapy followed by GEM or capecitabine-based chemoradiation in locally advanced pancreatic cancer) suggest that the radiotherapy combined with fluoropyrimidines achieves better results than when combined with GEM  (IA). Patients who are candidates for chemotherapy with limitations have a very poor prognosis and should be managed with either single agent chemotherapy (GEM alone), combination therapy (GEM + nab paclitaxel) or radiation therapy alone (Table 2).
Management of patients with metastatic disease
First line treatment The management of patients with advanced PDAC is based on systemic chemotherapy. In those patients who have received prior adjuvant or neadjuvant treatment, rechallenge should be considered when the disease-free interval is ≥6 months. Prior to treatment initiation, patients should be classified based on performance status, nutritional status, age and comorbidities according to Table 2. For patients able to receive chemotherapy without limitations, the current standard of care is either GEM-nab paclitaxel or FOLFIRINOX [35, 46] (IA). In the lack of randomized studies comparing these two regiments no one can be recommended [90, 91]. FOLFIRINOX should not be administered to patients >75 years old. In addition, this regimen is associated with a higher incidence of toxicity and thromboembolic complications and often requires growth factor support. FOLFIRINOX should be used with caution in patients with biliary stents who have increased risk of biliary tract infections and sepsis. In addition, it is recommended to administer antiemetic prophylaxis at least for moderately emetogenic chemotherapy. Patients who are candidates to chemotherapy with limitations are best managed with GEM-nab paclitaxel, and should be administered until progression or unacceptable toxicity; this is particularly the case for patients with ECOG 2 secondary to high tumor volume in whom tumor reduction may result in symptomatic improvement (IIB). Patients with ECOG 2 secondary to comorbidities or those with severe peripheral neuropathy can be treated with GEM alone (IIIB). Patients who are not candidates for chemotherapy should receive palliative treatment. The optimal management should always be reassessed and modified if the condition of the patient changes. Thus, subjects whose condition improves should be considered for more aggressive approaches. In any group, enrollment in a clinical trial should always be the preferred option (Algorithm 2). Open image in new window
Second line treatment Second line treatment is in general recommended after progression to first line treatment  (IA). Treatment decision should be based on the general status of the patient as well as the first line treatment. For patients who have been treated with GEM based regimen FOLFOX chemotherapy has demonstrated improvement in survival as compared to 5-FU in the CONKO-003 study . These results, however, have not been confirmed in the PANCREOX trial . More recently, the NAPOLI-1 showed that MM-398 (liposomal formulation of irinotecan) in combination with 5-FU/LV is better than 5-FU/LV alone . For patients who have received 5-FU/LV based chemotherapy on the first lie sett, there is very little data to base second line choices. In general, either GEM alone or GEM combination is recommended .
Treatment monitoring The response to treatment should be monitored every 8–12 weeks by a CT scan of the chest, abdomen and pelvis (IIIB). Other imaging modalities such as MRI and/or PET are not routinely recommended to be used in a serial basis (IIIB). The tumor marker CA 19.9 should be measured before treatment and every 4–8 weeks thereafter (IIIB). Tumor progression in patients with rising CA 19.9 should be confirmed radiologically [7, 35, 46, 97] (IIIB).
Bile duct obstruction.
Pain management strategies (IIA)
NSAIDs: Taking into account maximum doses and side effects (gastrointestinal bleeding, nephrotoxicity  acetaminophen
Opioids: any opioid as first choice, except for methadone (secondary choice). Methadone has great benefit in neuropathic pain due to its anti NMDA effect. Should be administered by trained personnel
Gabapentine (if neuropathic pain)
To manage moderate to severe pain
Lower frequency of secondary adverse events, with better pain control 
First choice: hydromorphone, ziconotide, local anesthetic
Severe neuropathic pain: baclofen, clonidine
Miscellaneous (little evidence)
Other therapies: phentolamine, capsaicin, cryoablation, acupuncture
Indicated for management of refractory pain, especially in patients with good performance status and localized pain caused by isolated metastases or pancreas and adjacent structures involvement
Celiac plexus block 
Provides better analgesic control (benefit in >80% of the patients) and/or decreases the opioid dose when compared to standard analgesic treatment
Cause a disruption in the pain signaling by an average of 3 months
It can be performed via percutaneous under ultrasound control, surgical or endoscopic by ultrasound. In terms of technique, there isn’t enough evidence to make any recommendations Side effects are rare (transient hypotension, constipation or diarrhea)
There is no evidence to recommend the timing for the blockage (early, at diagnosis, or late when there is poor pain control)
There is no evidence that increases survival
In the clinical practice celiac plexus block is reserved for patients with poor pain control despite escalation with opioids or for those with opioid related secondary adverse events 
There are limited data regarding the repeated use of celiac plexus block (pain relief is achieved in 29% of the patients)
Malnourishment is very common in patients with PADC secondary to problems with intake as well as cancer-associated cachexia. Frequent assessment of nutritional status is recommended, being Patient-Generated Subjective Global Assessment (PG-SGA) the most common scale used in oncology . Intervention ranges from dietary counseling, dietary supplements and enteral feeding. Parenteral nutrition is only recommended as a temporary approach in patients with transient inability for enteral feeding with good general status. For patients scheduled to undergo surgery who present with severe malnutrition (weight loss >10% in 6 months, BMI <18.5 kg/m2 and serum albumin <3 g/dl) it is recommended to provide nutritional support by dietary supplements, enteral feeding or parenteral feeding for 7–14 days. More than 50% with PADC have pancreatic exocrine insufficiency. This problem usually presents as esteatorrhea. Optimal substitutive treatment with substitute pancreatic enzymes is recommended (25,000–150,000 units per meal intake) .
Thromboembolic disease (TED) is one of the most common complications, with an incidence of 20–35% . Its etiology is multifactorial, being associated with poor prognosis, particularly in patients with early thrombosis. The risk of TED increase in the perioperative period in patients with advanced disease and in those treated with chemotherapy. An elevated D-dymer, poor performance status, central catheter and absence of prophylaxis increases the risk. The Khorana index is useful to identify high risk patients . In randomized clinical trials, prophylaxis of deep venous thrombosis (DVT) in patients with PDAC resulted in significant decrease in the rate of thrombosis, with no impact on survival [121, 122]. Routine prophylaxis of thrombosis is not recommended in the ambulatory setting  (IA). In patients with a Khorana index ≥3 and no risk of bleeding, prophylaxis with low molecular weight heparin could be considered (IIB). Hospitalized patients and those who underwent surgery treatment with low molecular weight heparin are recommended for at least 6 months (IIA).
The authors thank Sofía Perea, Pharm D, PhD, for her support in writing the manuscript. Funding was provided by Fundación ECO.
Compliance with ethical standards
Conflict of interest
The authors declare to have no conflict of interest.
The support for medical writing was supported by Fundación ECO.
Research involving human participants and/or animals
- 1.http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed Feb 2016.
- 2.GLOBOCAN. European age-standardised rates calculated by the statistical information team at cancer research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC, version 1.2. http://globocan.iarc.fr. Accessed May 2016.
- 19.Fernández-del Castill. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer. 2015. (Up To Date: August journal).Google Scholar
- 28.Yu J, Blackford AL, Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;0:1–7.Google Scholar
- 30.Estrategia en Cáncer del Sistema Nacional de Salud. Ministerio de Sanidad y Política Social, 2010. http://www.msssi.gob.es/organizacion/sns/planCalidadSNS/pdf/ActualizacionEstrategiaCancer.pdf. Accessed April 2016.
- 31.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. V 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 30 Dec 2015.
- 32.American Joint Committee on Cancer (AJCC) TNM staging system, September 6, 2013. American Cancer Society. http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-staging. Accessed 30 Dec 2015.
- 49.Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PWT, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794–801.PubMedPubMedCentralCrossRefGoogle Scholar
- 59.http://www.umassmed.edu/surgery/toolbox/panc_mortality_custom/. Acceso del 18 Feb 2016.
- 69.Duelge K, Krepline AN, Mahmoud A (2014) Survival benefit of adjuvant therapy for resectable pancreatic cancer (RPC) patients treated with neoadjuvant Therapy. In: Oncology 67th annual Cancer Symposium of the Society of Surgical Oncology Phoenix. Annals of Surgical Oncology; Poster P173.Google Scholar
- 70.Roland CL, Katz MH, Tzeng CD, Lin H, Varadhachary GR, Shroff R, et al. The addition of postoperative chemotherapy is associated with improved survival in patients with pancreatic cancer treated with preoperative therapy. Ann Surg Oncol. 2015. [Epub ahead of print].Google Scholar
- 72.Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918–22.PubMedPubMedCentralCrossRefGoogle Scholar
- 76.Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2016;34 (abstr LBA4006).Google Scholar
- 81.Herman JM, Swartz MJ, Hsu CC. Analysis of fluoruracil based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–10.PubMedPubMedCentralCrossRefGoogle Scholar
- 88.Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Comparison of Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol. 2013;31:LBA4003.CrossRefGoogle Scholar
- 89.Mukherjee S, Hurt C, Griffiths G, Bridgewater JA, Crosby T, Falk S, et al. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC). J Clin Oncol. 2013;31:LBA146.CrossRefGoogle Scholar
- 90.Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill S, Ruan JY, et al. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Am J Clin Oncol. 2015. [Epub ahead of print].Google Scholar
- 91.Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park). 2014;28(1):70–4.Google Scholar
- 93.Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 Trial. J Clin Oncol. 2014;32:2423–9.PubMedCrossRefGoogle Scholar
- 94.Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind SK, Zulfigar M, et al. PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). J Clin Oncol. 2014;32(5s):A4022.Google Scholar
- 95.Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–57.PubMedCrossRefGoogle Scholar
- 99.Sarfeh IJ, Rypins EB, Jakowatz JG. A prospective, randomized clinical investigation of cholecystoenterostomy and choledochoenterostomy. Am Surg. 1989;55:55–60.Google Scholar
- 104.Tol JAMG, van Hooft JE, Timmer R, Kubben FJ, van der Harst E, de Hingh IH, et al. Metal or plastic stents for preoperative biliary drainage in respectable pancreatic cancer. Gut Aug. 2015. (25 Published Online First).Google Scholar
- 108.Van Hooft JE, Uitdehaag MJ, Bruno MJ, Timmer R, Siersema PD, Dijkgraaf MG, et al. Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc. 2009;69:1059–66.PubMedCrossRefGoogle Scholar
- 111.Smith TJ, Staats PS, Deer T, Steams LJ, Rauck RL, Boortz-Mary RL, et al. Implantable drug delivery systems study group. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040–9.PubMedCrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.